“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”
– NR4A1 和 NR4A2 的药理学靶向激活胶质母细胞瘤治疗反应 –
基本信息
- 批准号:10744524
- 负责人:
- 金额:$ 50.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-19 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:Adoptive TransferAdultAutomobile DrivingBioinformaticsBiological AssayBiologyCancer ModelCarcinomaCell LineCell ProliferationCell physiologyCellsCessation of lifeClinical TrialsDataDrug KineticsExhibitsFutureGene ExpressionGenesGeneticGlioblastomaGoalsHumanIL8 geneImmuneImmune EvasionImmune checkpoint inhibitorImmune responseImmunooncologyImmunosuppressionImmunotherapyIndolesInfiltrationInvadedLeadLigandsMacrophageMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of brainMeasuresMediatingMesenchymalMesenchymal Cell NeoplasmModelingMolecularMusMyeloid CellsMyeloid-derived suppressor cellsNR4A1 geneNR4A2 geneNuclear Orphan ReceptorOrphan Nuclear Receptor GeneOutcomePatientsPharmaceutical ChemistryPharmaceutical PreparationsPhenotypePre-Clinical ModelPreclinical TestingProductionProliferatingPropertyRadiation therapyReceptor InhibitionRegulationRegulatory T-LymphocyteResistanceRoleSeriesSignal TransductionT cell differentiationT-LymphocyteTWIST1 geneTestingTherapeuticToxic effectTumorigenicityantagonistanti-cancerbioinformatics toolcandidate identificationcheckpoint therapychemoradiationconventional therapycytokinecytotoxicityexhaustexhaustionimprovedin vivoin vivo evaluationknock-downloss of functionmigrationmultidisciplinaryneoplastic cellneuro-oncologynovelnovel strategiesnovel therapeuticspharmacologicpre-clinicalprogrammed cell death ligand 1programsradiation resistancereceptorreceptor expressionresponseself-renewalsingle-cell RNA sequencingstandard of carestem cell self renewalstemnesstemozolomidetherapy resistanttreatment responsetumortumor growthtumor microenvironmenttumor-immune system interactions
项目摘要
Resistance to standard of care (SOC) temozolomide (TMZ) and radiation treatment (XRT) limits survival of the
most common adult brain cancer, glioblastoma (GBM), to 12-18 months. Despite promising results in other
cancers, robust immunosuppression in GBM has also limited the responses to immune checkpoint inhibitors
(ICIs). Reciprocal interactions in the GBM tumor microenvironment (TME) between mesenchymal changes and
immunosuppression enhance resistance to chemoradiation and immunotherapy, respectively. Therefore, a
compelling therapeutic strategy for GBM is to concurrently reprogram the mesenchymal and immune
suppressive TMEs and potentiate ICI and SOC therapy. The NR4A1 and NR4A2 orphan nuclear receptors are
compelling targets to achieve this goal. We synthesized a series of novel bis-indole–derived ligands (CDIMs)
with potent dual antagonism of NR4A1 and NR4A2 and negligible in vivo toxicity, of which six demonstrated nM
range KDs for both receptors. Genetic based NR4A 1 and 2 loss of function strongly activates anti-cancer
immune responses by reversing T-cell exhaustion which underlies poor ICI responses in GBM. In addition,
NR4A1/2 promote EMT in other cancers which contributes to chemoradiation resistance. Finally, high levels of
NR4A1/2 expression in GBM are strongly associated with decreased patient survival after conventional
treatments. Therefore, we propose to test the hypothesis that CDIM inhibition of NR4A1/2 reprograms the
GBM TME and potentiates ICI and TMZ/XRT responses. Further NR4A1/2 upregulates PD-L1 and TWISt1,
key regulators of GBM immune suppression and mesenchymal phenotypes, respectively. Preliminary studies
demonstrated that CDIMs inhibit PD-L1 and TWIST1 expression, reverse immune suppressive myeloid and T
cell phenotypes and prolong survival of experimental GBMs. We will test our hypothesis by i) identifying lead
dual NR4A1/2 CDIM compounds based on inhibition of malignant and mesenchymal GBM cell properties
(proliferation, self-renewal, invasion) and reversal of dysfunctional T cell phenotypes in vivo (Aim 1), ii)
establishing the functional impact of NR4A1/2 CDIMs to reprogram the immune suppressive and mesenchymal
TME (Aim 2) and iii) quantifying the effects of NR4A1/2 CDIMs to potentiate ICI and SOC responses in mouse
GBM syngeneic models and define the role of PD-L1 and TWIST1 in their mechanisms of action (Aim 3).
Quantification of potency, pharmacokinetics and preclinical anti-tumor activity alone and in combination with to
standard of care TMZ-XRT and ICIs is expected to identify candidate CDIMs for consideration in future clinical
trials. Through application of powerful bioinformatic tools that model the cancer TME through integration of
scRNAseq, cyTOF and IMC data, these studies are expected to shed new light on novel mechanisms by which
mesenchymal and immune suppressive TMEs interact to coordinately drive treatment resistance in GBM through
NR4A1/2. To achieve our goals, we assembled a unique multidisciplinary team with expertise in medicinal
chemistry, neuro-oncology, GBM biology and preclinical modeling, and immuno-oncology.
对标准治疗(SOC)替莫唑胺(TMZ)和放射治疗(XRT)的耐药性限制了患者的生存期。
最常见的成人脑癌,胶质母细胞瘤(GBM),到12-18个月。尽管在其他方面取得了可喜的成果,
在癌症中,GBM中的强大免疫抑制也限制了对免疫检查点抑制剂的反应
(ICIs)。GBM肿瘤微环境(TME)中间充质变化与
免疫抑制分别增强了对放化疗和免疫疗法抵抗力。因此
令人信服的GBM治疗策略是同时重编程间充质和免疫细胞,
抑制性TME并增强ICI和SOC治疗。NR 4A 1和NR 4A 2孤儿核受体是
为实现这一目标而制定的强制性目标。我们合成了一系列新型的双吲哚衍生配体(CDIMs)
具有NR 4A 1和NR 4A 2的强效双重拮抗作用,体内毒性可忽略不计,其中6个显示nM
两种受体的KD范围。基于遗传的NR 4A 1和2功能丧失强烈激活抗癌作用
通过逆转T细胞耗竭(其是GBM中不良ICI应答的基础)来增强免疫应答。此外,本发明还提供了一种方法,
NR 4A 1/2在其他癌症中促进EMT,这有助于化疗和放疗抗性。最后,高水平的
GBM中的NR 4A 1/2表达与常规化疗后患者存活率降低密切相关。
治疗。因此,我们建议检验CDIM抑制NR 4A 1/2重编程NR 4A 1/2的假设。
GBM TME和增强ICI和TMZ/XRT反应。此外,NR 4A 1/2上调PD-L1和TWISt 1,
GBM免疫抑制和间充质表型的关键调节因子。初步研究
证明CDIM抑制PD-L1和TWIST 1表达,逆转免疫抑制性骨髓和T细胞
细胞表型和延长实验GBM的存活。我们将通过i)识别铅
基于抑制恶性和间充质GBM细胞特性的双重NR 4A 1/2 CDIM化合物
(增殖、自我更新、侵袭)和体内功能失调的T细胞表型的逆转(目的1),ii)
建立NR 4A 1/2 CDIM重编程免疫抑制和间充质细胞的功能影响,
iii)量化NR 4A 1/2 CDIM增强小鼠ICI和SOC应答的作用
GBM同基因模型,并定义PD-L1和TWIST 1在其作用机制中的作用(目的3)。
单独和与以下药物组合的效力、药代动力学和临床前抗肿瘤活性的定量:
标准治疗TMZ-XRT和ICI有望识别候选CDIM,供未来临床研究考虑。
审判通过应用强大的生物信息学工具,通过整合
scRNAseq、cyTOF和IMC数据,这些研究有望揭示新的机制,
间充质和免疫抑制性TME相互作用,通过以下途径协调驱动GBM中的治疗抗性:
NR4A1/2。为了实现我们的目标,我们组建了一个独特的多学科团队,拥有医学方面的专业知识,
化学、神经肿瘤学、GBM生物学和临床前建模以及免疫肿瘤学。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrei M Mikheev其他文献
Andrei M Mikheev的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrei M Mikheev', 18)}}的其他基金
Generation of TWIST1 reporters through characterization of TWIST1 dependent netwo
通过表征 TWIST1 依赖网络生成 TWIST1 报告基因
- 批准号:
8719192 - 财政年份:2013
- 资助金额:
$ 50.34万 - 项目类别:
Generation of TWIST1 reporters through characterization of TWIST1 dependent netwo
通过表征 TWIST1 依赖网络生成 TWIST1 报告基因
- 批准号:
8637397 - 财政年份:2013
- 资助金额:
$ 50.34万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 50.34万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 50.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)